It will take about four months to build out the 17,708-square-foot space; the foundation expects to move in during August.

Patients undergoing BRAF/MEK inhibitor therapy for melanoma more commonly experience VKH-like uveitis compared with other malignancy types.

FORE Biotherapeutics has announced that two abstracts on its investigational therapy plixorafenib will be presented at the ...

Skin cancer advanced clinical practitioners ensure continuity of care for patients with malignant melanoma and other advanced ...

Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes.

Cracking the code of melanoma's drug escape Melanoma, the deadliest form of skin cancer, is often driven by mutations in the ...

Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET. Company Participants. Douglas Onsi - President ...

In this video, Michael Cecchini, MD, discusses the significance of results from the phase 3 BREAKWATER trial, which were presented at ASCO Gastrointestinal Cancers Symposium.

PR Newswire SAN FRANCISCO and SUZHOU, China, March 30, 2025 SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...